Anastrozole tablets

Listing ID #1314546

Get Latest Price

Supply Type Manufacturer, Exporter, Supplier
Preferred Buyer Location All over the world

The company is a reputed Supplier and Exporter of Anastrozole Tablets. Anastrozole Tablets are indicated for metastatic breast cancer or as first-line treatment of menopausal women. Our company makes Anastrozole Tablets available in well-sealed packaging. Also, Anastrozole Tablets are offered by us at industry leading prices.

View More Details

Send Enquiry

Product Details

Details

Generic Name	Anastrozole
Brand Name	Altraz Tablet
Strength Available	1 MG
Packing	14 Tablet
Name of Company	Alkem Laboratories Ltd.
Classification	Nonsteroidal aromatase inhibitor
Mechanism of Action	Potent and selective nonsteroidal inhibitor of aromatase. Inhibits the synthesis of estrogens by inhibiting the conversion of adrenal androgens (androstenedione and testosterone) to estrogens (estrone, estrone sulfate, and estradiol). Serum estradiol levels are suppressed by 90% within 14 days, and nearly compietely suppressed after 6 weeks of therapy. No inhibitory effect on adrenal corticosteroid or aldosterone biosynthesis .
Mechanism of Resistance	None characterized.
Absorption	Excellent bioavailability via the oral route, with 85% of a dose absorbed within 2 hours of ingestion. Absorption is not affected by food.
Distribution	Widely distributed throughout the body. About 40% of drug is bound to plasma proteins.
Metabolism	NonExtensively metabolized in the liver (up to 85%) by N-dealkylation, hydroxylation, and glucuronidation, to inactive forms. Han-life of drug is about 50 hours. Steady-state levels of drug are achieved after 7 days of a once-daily administration. The major route of elimination is fecal, with renal excretion accounting for only 10% of drug ciearance.
Indications & Usage	Metastatic breast cancer - First-line treatment of postmenopausal women with estrogenreceptor positive or estrogen-receptor unknown disease. Metastatic breast cancer - Postmenopausal women with estrogen-receptor positive, advanced disease, and proqression while on tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone-receptor positive early-stage breast cancer.
Dosage Range	Usual dose is 1 mg PO qd for both first-line and second-line therapy
Drung Preparation	Available as a 1 mg white, film-eoated tabiet for oral use.
Drung Interaction	None known.
Special Considerations	No dose adjustments are required for patients with either hepatic or renal dysfunction. Caution patients about the risk of hot fiashes. No need for glucocorticoid and/or mineralocorticoid replacement. Pregnancy category D.
Toxicity	Asthenia. Most common toxicity, occurs in 1%-20%. Mild nausea and vomiting. Constipation or diarrhea can also occur. Hot fiushes. Occurs in 10% of patients. Dry, scaling skin rash. Arthralgias occur in 10%-15% of patients involving hands, knees, hips, lower back, and shoulders. Early morning stiffness is usual.